Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvementSimona Soverini, Giovanni Martinelli, Marzia Salvucci et al.|Cancer|2013Cited by 143
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphomaCristina Papayannidis, Giovanni Martinelli|Blood Cancer Journal|2015Cited by 119
Diagnostic capabilities, clinical features, and longitudinal <scp><i>UBA1</i></scp> clonal dynamics of a nationwide <scp>VEXAS</scp> cohortCarmelo Gurnari, Maria Teresa Voso, Maria Rosaria Pascale et al.|American Journal of Hematology|2023Cited by 43
Methodology and clinical utility of longitudinal <scp><i>UBA1</i></scp> tracking in <scp>VEXAS</scp> syndromeCarmelo Gurnari, Maria Teresa Voso, Elisa Galossi et al.|British Journal of Haematology|2024Cited by 10